journal article·2019-07-08

Zinc Gluconate-Loaded Chitosan Nanoparticles Reduce Severity of Collagen-Induced Arthritis in Wistar Rats

Md. Meraj Ansari, Anas Ahmad, Rakesh Kumar Mishra, Syed Shadab Raza, Rehan Khan

Publisher page

Abstract

Rheumatoid arthritis (RA) is the most prevalent autoimmune disease affecting about 1% world population. Zinc (Zn) is necessary for the maintenance of bone homeostasis and the level of Zn was reported to be decreased in RA patients and collagen-induced arthritic rats. Effective delivery of Zn has been reported using zinc gluconate but oral absorption of Zn from zinc gluconate (ZG) is very low in humans. Zn supplementation reduces disease severity in patients suffering from chronic, refractory RA and exerts mild and transient side effects. The aim of this study was to synthesize and characterize zinc gluconate-loaded chitosan nanoparticles (ZG-Chit NPs) and to evaluate and compare therapeutic efficacy of ZG-Chit NPs and zinc gluconate against collagen-induced RA in Wistar rats. The nanoparticles were formulated by ionic gelation method and the hydrodynamic diameter was 106.5 ± 79.55 nm as measured using DLS. The particle size, shape, and surface morphology was further confirmed by transmission electron microscopy, scanning electron microscopy, and atomic force microscopy. These nanoparticles showed good cytocompatibility against foreskin fibroblasts (BJ) and L929 cells. Arthritic rats were treated with ZG (20 mg/kg body weight, intraperitoneally) and equivalent doses of ZG-Chit NPs. The treatment of both ZG and ZG-Chit NPs reduced the severity of arthritis as evidenced by reduced joint swelling, erythema, and edema but ZG-Chit NPs exhibited superior efficacy. Furthermore, it was found that ZG and ZG-Chit NPs attenuate biomarkers of inflammation (C-reactive protein, myeloperoxidase, nitric oxide, TNF-α, and IL-1β) and oxidative stress (articular elastase, lipid peroxidation, catalase, glutathione, and superoxide dismutase). The results of the histopathology further confirmed that ZG-Chit NPs markedly suppressed infiltration of inflammatory cells as compared to ZG at the ankle joint tissue. Immunohistochemical analysis also revealed that treatment with ZG-Chit NPs resulted in reduced pro-inflammatory marker (TNF-α, IL-6, and iNOS) expression and enhanced SOD1 expression. Overall, this study suggests that ZG and ZG-Chit NPs suppressed the severity of arthritis plausibly mediated by attenuation of inflammation and oxidative stress and more importantly ZG-Chit NPs exhibited superior efficacy as compared to ZG.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Rheumatoid Arthritis Research and Therapies · Autoimmune and Inflammatory Disorders Research · Inflammatory Bowel Disease

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Institute of Nano Science and Technology, Habitat Centre, Phase 10, Sector 64, Mohali, Punjab 160062, India

Laboratory for Stem Cell and Restorative Neurology, Department of Biotechnology, Era’s Lucknow Medical College Hospital, Sarfarazganj, Lucknow 226003, India

Funding

Science and Engineering Research Board · Nano Mission Council, Department of Science and Technology

References (64)

Show source-provided references
1. 10.1038/nature0166110.1038/nature01661 ↗
2. 10.1111/j.1365-2249.2005.02940.x10.1111/j.1365-2249.2005.02940.x ↗
3. 10.1186/ar417410.1186/ar4174 ↗
4. 10.1038/nrrheum.2016.17510.1038/nrrheum.2016.175 ↗
5. 10.1080/13543784.2017.127656210.1080/13543784.2017.1276562 ↗
6. 10.1007/s40744-017-0073-310.1007/s40744-017-0073-3 ↗
7. 10.1007/s12263-011-0231-010.1007/s12263-011-0231-0 ↗
8. 10.1007/s11010-011-0852-z10.1007/s11010-011-0852-z ↗
9. 10.1016/j.autrev.2014.11.00810.1016/j.autrev.2014.11.008 ↗
10. 10.1007/s12011-015-0325-410.1007/s12011-015-0325-4 ↗
11. Pandey S. · Indian J. Med. Res. · 1985
12. 10.1007/s12011-016-0746-810.1007/s12011-016-0746-8 ↗
13. Honkanen V. · Clin. Exp. Rheumatol. · 1989 · 7 · 465
14. Alorainy M. · Int. J. Health Sci. · 2008 · 2 · 59
15. 10.1016/S0140-6736(76)91793-110.1016/S0140-6736(76)91793-1 ↗
16. 10.3109/0300974750916526410.3109/03009747509165264 ↗
17. 10.1136/ard.39.4.32910.1136/ard.39.4.329 ↗
18. 10.1111/j.1365-2133.1980.tb07264.x10.1111/j.1365-2133.1980.tb07264.x ↗
19. 10.1002/ajhb.1019910.1002/ajhb.10199 ↗
20. 10.1007/BF0278460410.1007/BF02784604 ↗
21. 10.1007/BF0197494610.1007/BF01974946 ↗
22. 10.1016/j.freeradbiomed.2004.07.00710.1016/j.freeradbiomed.2004.07.007 ↗
23. 10.3945/ajcn.2009.2883610.3945/ajcn.2009.28836 ↗
24. 10.1097/MCO.0b013e32833cf3bc10.1097/MCO.0b013e32833cf3bc ↗
25. 10.1016/j.jnutbio.2009.02.00110.1016/j.jnutbio.2009.02.001 ↗
26. 10.1080/07315724.1998.1071875810.1080/07315724.1998.10718758 ↗
27. Milanino R. · Clin. Exp. Rheumatol. · 1993 · 11 · 271
28. 10.1007/BF0203107210.1007/BF02031072 ↗
29. 10.1021/acsbiomaterials.5b0050210.1021/acsbiomaterials.5b00502 ↗
30. 10.1186/s12964-018-0238-x10.1186/s12964-018-0238-x ↗
31. 10.17140/TFMOJ-1-e00510.17140/TFMOJ-1-e005 ↗
32. 10.2174/156800961766617063014193110.2174/1568009617666170630141931 ↗
33. 10.1021/acsbiomaterials.5b0016310.1021/acsbiomaterials.5b00163 ↗
34. 10.1021/acsbiomaterials.6b0071610.1021/acsbiomaterials.6b00716 ↗
35. 10.1021/bm101584c10.1021/bm101584c ↗
36. 10.1021/acsbiomaterials.7b0026210.1021/acsbiomaterials.7b00262 ↗
37. 10.1021/acsbiomaterials.7b0078010.1021/acsbiomaterials.7b00780 ↗
38. 10.1021/bm800276d10.1021/bm800276d ↗
39. 10.1002/(SICI)1097-4628(19970103)63:1<125::AID-APP13>3.0.CO;2-410.1002/(SICI)1097-4628(19970103)63:1<125::AID-APP13>3.0.CO;2-4 ↗
40. 10.1021/acsbiomaterials.8b0108110.1021/acsbiomaterials.8b01081 ↗
41. 10.1021/acs.biomac.7b0160710.1021/acs.biomac.7b01607 ↗
42. 10.1038/nprot.2007.17310.1038/nprot.2007.173 ↗
43. 10.1073/pnas.96.8.452410.1073/pnas.96.8.4524 ↗
44. 10.1080/107157602100004664010.1080/1071576021000046640 ↗
45. 10.1186/ar74810.1186/ar748 ↗
46. 10.1111/imj.1967.16.3.20010.1111/imj.1967.16.3.200 ↗
47. Sedlak J. · Endocrinol. Exp. · 1982 · 16 · 103
48. 10.1016/j.taap.2018.07.01010.1016/j.taap.2018.07.010 ↗
49. 10.1016/0003-2697(71)90370-810.1016/0003-2697(71)90370-8 ↗
50. Claiborne A. · 1985 · 283
51. 10.1016/S0009-8981(98)00060-610.1016/S0009-8981(98)00060-6 ↗
52. 10.1006/clim.1999.469610.1006/clim.1999.4696 ↗
53. 10.1016/j.cbi.2015.06.00110.1016/j.cbi.2015.06.001 ↗
54. Knight J. A. · Ann. Clin. Lab. Sci. · 2000 · 30 · 145
55. 10.1074/jbc.272.12.761710.1074/jbc.272.12.7617 ↗
56. 10.1016/j.exger.2007.10.01310.1016/j.exger.2007.10.013 ↗
57. 10.1097/WOX.0b013e318243961310.1097/WOX.0b013e3182439613 ↗
58. 10.1002/cbf.155010.1002/cbf.1550 ↗
59. 10.1016/S0378-8741(01)00221-510.1016/S0378-8741(01)00221-5 ↗
60. 10.1186/1476-9255-5-910.1186/1476-9255-5-9 ↗
61. 10.1254/jphs.CRJ06009X10.1254/jphs.CRJ06009X ↗
62. 10.1007/s12291-015-0514-010.1007/s12291-015-0514-0 ↗
63. 10.1111/j.1532-5415.2011.03570.x10.1111/j.1532-5415.2011.03570.x ↗
64. 10.1684/mrh.2018.043810.1684/mrh.2018.0438 ↗